Literature DB >> 11504836

Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.

A Sapino1, L Righi, P Cassoni, M Papotti, P Gugliotta, G Bussolati.   

Abstract

Neuroendocrine (NE) breast carcinomas are a rare entity in young women; however, their frequency increases in aged patients. The present work demonstrates that NE breast carcinomas in elderly women can also express an apocrine immunophenotype and analyzes the histological and clinical aspects of such differentiation. A selected series of 50 NE tumors (positive for NE markers in >/=50% of the cells) was tested for the immunocytochemical expression of gross cystic disease fluid protein-15 (GCDFP-15). The results demonstrated that about 50% of moderately (G2) and well-differentiated (G1) NE breast carcinomas (mucinous, solid papillary, and solid cohesive histotypes) coexpressed the apocrine marker. In these cases, specific mRNA for GCDFP-15 (PIP) and for chromogranin A (ChA) was demonstrated using in situ hybridization (ISH). Carcinomas of the alveolar subtype (G2) and poorly differentiated carcinomas (G3), including one case of atypical carcinoid, were pure NE carcinomas, devoid of apocrine differentiation. The steroid receptor status of these lesions was evaluated to test a possible involvement of androgen receptors in apocrine differentiation. We demonstrated that the level of AR and the mean age of patients at diagnosis were significantly higher in apocrine than in nonapocrine differentiated tumors. The histological grade and the expression of estrogen receptor (ER) significantly influenced the prognosis of these NE carcinomas, either pure or NE-apocrine differentiated. The most original result of our study is therefore the demonstration of a possible divergent apocrine differentiation of NE breast carcinomas that might be regulated by the activation of androgen receptors in elder patients. In addition, the possibility for using Chs or GCDFP-15 serum values in the follow-up of these patients, as demonstrated in two cases of the present series, can justify the immunophenotyping of the tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504836     DOI: 10.1038/modpathol.3880387

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  31 in total

1.  Solid papillary carcinoma of the breast: imprint cytological and histological findings.

Authors:  Naoto Kuroda; Nokiaki Fujishima; Kaori Inoue; Masahiko Ohara; Keiko Mizuno; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

2.  Human achaete-scute homolog-1 expression in neuroendocrine breast carcinoma.

Authors:  Luisella Righi; Ida Rapa; Arianna Votta; Mauro Papotti; Anna Sapino
Journal:  Virchows Arch       Date:  2012-03-16       Impact factor: 4.064

3.  The genetic landscape of breast carcinomas with neuroendocrine differentiation.

Authors:  Caterina Marchiò; Felipe C Geyer; Charlotte Ky Ng; Salvatore Piscuoglio; Maria R De Filippo; Marco Cupo; Anne M Schultheis; Raymond S Lim; Kathleen A Burke; Elena Guerini-Rocco; Mauro Papotti; Larry Norton; Anna Sapino; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2016-12-26       Impact factor: 7.996

4.  Neuroendocrine carcinoma of the breast with a mucinous carcinoma component: A case report with review of the literature.

Authors:  Mitsuaki Ishida; Tomoko Umeda; Hajime Abe; Tohru Tani; Hidetoshi Okabe
Journal:  Oncol Lett       Date:  2012-04-12       Impact factor: 2.967

5.  Bilateral primary breast neuroendocrine carcinoma in a young woman: report of a case.

Authors:  Jiang-Yu Zhang; Wen-Jing Chen
Journal:  Surg Today       Date:  2011-10-04       Impact factor: 2.549

Review 6.  The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms.

Authors:  Marco Volante; Guido Rindi; Mauro Papotti
Journal:  Virchows Arch       Date:  2006-10-11       Impact factor: 4.064

Review 7.  Primary neuroendocrine breast cancer, how much do we know so far?

Authors:  Homam Alkaied; Kassem Harris; Basem Azab; Qun Dai
Journal:  Med Oncol       Date:  2012-04-01       Impact factor: 3.064

Review 8.  Working formulation of neuroendocrine tumors of the skin and breast.

Authors:  Sofia Asioli; Maria Pia Foschini; Riccardo Masetti; Vincenzo Eusebi
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

9.  Primary neuroendocrine tumor of the breast: imaging features.

Authors:  Eun Deok Chang; Min Kyun Kim; Jeong Soo Kim; In Yong Whang
Journal:  Korean J Radiol       Date:  2013-05-02       Impact factor: 3.500

10.  Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.

Authors:  Marion Lavigne; Emmanuelle Menet; Jean-Christophe Tille; Marick Lae; Laetitia Fuhrmann; Claire Bonneau; Gabrielle Deniziaut; Samia Melaabi; Charlotte C K Ng; Caterina Marchiò; Roman Rouzier; Ivan Bièche; Anne Vincent-Salomon
Journal:  Mod Pathol       Date:  2017-09-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.